{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:00:54Z","timestamp":1792051254495,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cgh.2020.10.019","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T01:25:08Z","timestamp":1602811508000},"page":"2626-2635.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-1852","authenticated-orcid":false,"given":"Robert S.","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan Ram","family":"Bhamidimarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6950-8174","authenticated-orcid":false,"given":"Nikolaos","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Bukofzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-3681","authenticated-orcid":false,"given":"Jasmohan S.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.10.019_bib1","first-page":"142","article-title":"Hepatic encephalopathy: an update on the pathophysiology and therapeutic options","volume":"5","author":"Elwir","year":"2017","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cgh.2020.10.019_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.10.019_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.28414","article-title":"The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis","volume":"64","author":"Bajaj","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.10.019_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A\u00a0randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.10.019_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcrc.2009.01.008","article-title":"Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy","volume":"24","author":"Fichet","year":"2009","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cgh.2020.10.019_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756283X17743419","article-title":"Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients","volume":"11","author":"Ventura-Cots","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2020.10.019_bib7","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.10.019_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cld.468","article-title":"Hepatic encephalopathy: new treatments","volume":"5","author":"Hadjihambi","year":"2015","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.cgh.2020.10.019_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.mehy.2006.12.061","article-title":"L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy","volume":"69","author":"Jalan","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.cgh.2020.10.019_bib10","first-page":"CD012410","article-title":"L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"5","author":"Goh","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2020.10.019_bib11","series-title":"Xifaxan [package insert]","year":"2018"},{"key":"10.1016\/j.cgh.2020.10.019_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MCG.0b013e318299c789","article-title":"Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study","volume":"47","author":"Ventura-Cots","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2020.10.019_bib13","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/S0168-8278(12)60620-5","article-title":"Phase 1\/2A studies with OCR-002 (ornithine phenylacetate); optimized dosing regimen with an ammonia scavenger for treatment of hepatic encephalopathy [abstract 607]","volume":"56","author":"Hassanein","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.10.019_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/1756283X16658252","article-title":"Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients","volume":"9","author":"Ventura-Cots","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2020.10.019_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness. A practical scale","volume":"2","author":"Teasdale","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.10.019_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1365-2036.2012.05038.x","article-title":"Modified-orientation log to assess hepatic encephalopathy","volume":"35","author":"Salam","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.10.019_bib17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4254\/wjh.v7.i4.662","article-title":"Arrhythmia risk in liver cirrhosis","volume":"7","author":"Mozos","year":"2015","journal-title":"World J Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520314324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520314324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:30Z","timestamp":1761543390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520314324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1542356520314324"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.10.019","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}